Abstract

Systemic sclerosis (SSc) is a rare connective tissue disorder, which leads to progressive fibrosis of many organs. Its course is characterized by the presence of two classical autoantibodies: anti-topoisomerase I (ATA, Scl-70) and anti-centromere (ACA). In recent years, the presence of antibodies against a wider range of antigens was demonstrated, namely: RNA polymerase III, fibrillarin, NOR90, Th/To, PM-Scl-100, PM-Scl-75, Ku, PDGFR, but their clinical significance is relatively little known and until recently the methods of their assessment were available only in specialized laboratories. More and more reports in the literature indicate existence of links between the presence of selected autoantibodies with clinical correlations i.e. anti-RNA polymerase III with scleroderma renal crisis or anti-Ku and myositis, arthritis and joint contractures. The importance of autoantibodies in the diagnostic process was underlined by their inclusion into the new ACR/EULAR 2013 classification criteria for systemic sclerosis. This work reviews the current knowledge on the clinical significance of autoantibodies in systemic sclerosis.

References

• 1. Baroni S.S., Santillo M., Bevilacqua F., Luchetti M., Spadoni T.,Mancini M., Fraticelli P., Sambo P., Funaro A., Kazlauskas A., AvvedimentoE.V., Gabrielli A.: Stimulatory autoantibodies to the PDGFreceptor in systemic sclerosis. N. Engl. J. Med., 2006; 354: 2667-2676
  Google Scholar
• 2. Belizna C., Henrion D., Beucher A., Lavigne C., Ghaali A., LevesqueH.: Anti-Ku antibodies: clinical, genetic and diagnostic insights. AutoimmunRev., 2010; 9: 691-694
  Google Scholar
• 3. Bonroy C., Van Praet J., Smith V., Van Steendam K., Mimori T.,Deschepper E., Deforce D., Devreese K., De Keyser F.: Optimizationand diagnostic performance of a single multiparameter lineblot inthe serological workup of systemic sclerosis. J. Immunol. Methods,2012; 379: 53-60
  Google Scholar
• 4. Bunn C.C., Denton C.P., Shi-Wen X., Knight C., Black C.M.: Anti–RNA polymerases and other autoantibody specificities in systemicsclerosis. Br. J. Rheumatol., 1998; 37: 15-20
  Google Scholar
• 5. Ceribelli A., Cavazzana I., Franceschini F., Airo P., Tincani A., CattaneoR., Pauley B.A., Chan E.K., Satoh M.: Anti-Th/To are commonantinucleolar autoantibodies in Italian patients with scleroderma.J. Rheumatol., 2010; 37: 2071-2075
  Google Scholar
• 6. Classen J.F., Henrohn D., Rorsman F., Lennartsson J., LauwerysB.R., Wikstrom G., Rorsman C., Lenglez S., Franck-Larsson K., TomasiJ.P., Kampe O., Vanthuyne M., Houssiau F.A., Demoulin J.B.: Lack ofevidence of stimulatory autoantibodies to platelet-derived growthfactor receptor in patients with systemic sclerosis. Arthritis Rheum.,2009; 60: 1137-1144
  Google Scholar
• 7. Dagher J.H., Scheer U., Voit R., Grummt I., Lonzetti L., RaymondY., Senecal J.L.: Autoantibodies to NOR 90/hUBF: longterm clinicaland serological followup in a patient with limited systemic sclerosissuggests an antigen driven immune response. J. Rheumatol.,2002; 29: 1543-1547
  Google Scholar
• 8. Defendenti C., Atzeni F., Spina M.F., Grosso S., Cereda A., GuercilenaG., Bollani S., Saibeni S., Puttini P.S.: Clinical and laboratoryaspects of Ro/SSA-52 autoantibodies. Autoimmun. Rev., 2011; 10:150-154
  Google Scholar
• 9. Frank M.B., McCubbin V., Trieu E., Wu Y., Isenberg D.A., TargoffI.N.: The association of anti-Ro52 autoantibodies with myositis andscleroderma autoantibodies. J. Autoimmun., 1999; 12: 137-142
  Google Scholar
• 10. Fujii T., Mimori T., Akizuki M.: Detection of autoantibodies tonucleolar transcription factor NOR 90/hUBF in sera of patients withrheumatic diseases, by recombinant autoantigen-based assays. ArthritisRheum., 1996; 39: 1313-1318
  Google Scholar
• 11. Fujimoto M., Shimozuma M., Yazawa N., Kubo M., Ihn H., Sato S.,Tamaki T., Kikuchi K., Tamaki K.: Prevalence and clinical relevance of 52-kDa and 60-kDa Ro/SS-A autoantibodies in Japanese patientswith systemic sclerosis. Ann. Rheum. Dis., 1997; 56: 667-670
  Google Scholar
• 12. Gabrielli A., Avvedimento E.V., Krieg T.: Scleroderma. N. Engl. J.Med., 2009; 360: 1989-2003
  Google Scholar
• 13. Gabrielli A., Svegliati S., Moroncini G., Luchetti M., Tonnini C.,Avvedimento E.V.: Stimulatory autoantibodies to the PDGF receptor:a link to fibrosis in scleroderma and a pathway for novel therapeutictargets. Autoimmun. Rev., 2007; 7: 121-126
  Google Scholar
• 14. Hamaguchi Y.: Autoantibody profiles in systemic sclerosis: predictivevalue for clinical evaluation and prognosis. J. Dermatol.,2010; 37: 42-53
  Google Scholar
• 15. Hanke K., Bruckner C.S., Dahnrich C., Huscher D., KomorowskiL., Meyer W., Janssen A., Backhaus M., Becker M., Kill A., Egerer K.,Burmester G.R., Hiepe F., Schlumberger W., Riemekasten G.: Antibodiesagainst PM/Scl-75 and PM/Scl-100 are independent markersfor different subsets of systemic sclerosis patients. Arthritis Res.Ther., 2009; 11: R22
  Google Scholar
• 16. Hanke K., Dahnrich C., Bruckner C.S., Huscher D., Becker M., JansenA., Meyer W., Egerer K., Hiepe F., Burmester G.R., SchlumbergerW., Riemekasten G.: Diagnostic value of anti-topoisomerase I antibodiesin a large monocentric cohort. Arthritis Res. Ther., 2009; 11: R28
  Google Scholar
• 17. Hervier B., Rimbert M., Colonna F., Hamidou M.A., Audrain M.:Clinical significance of anti-Ro/SSA-52 kDa antibodies: a retrospectivemonocentric study. Rheumatology, 2009; 48: 964-967
  Google Scholar
• 18. Hesselstrand R., Scheja A., Wuttge D.M.: Scleroderma renal crisisin a Swedish systemic sclerosis cohort: survival, renal outcome,and RNA polymerase III antibodies as a risk factor. Scand. J. Rheumatol.,2012; 41: 39-43
  Google Scholar
• 19. Hudson M., Mahler M., Pope J., You D., Tatibouet S., Steele R.,Baron M., Canadian Scleroderma Research Group, Fritzler M.: Clinicalcorrelates of CENP-A and CENP-B antibodies in a large cohortof patients with systemic sclerosis. J. Rheumatol., 2012; 39: 787-794
  Google Scholar
• 20. Koschik R.W.2nd, Fertig N., Lucas M.R., Domsic R.T., MedsgerT.A.Jr.: Anti-PM-Scl antibody in patients with systemic sclerosis.Clin. Exp. Rheumatol., 2012; 30 (Suppl. 71): S12-S16
  Google Scholar
• 21. Kuwana M., Kaburaki J., Mimori T., Tojo T., Homma M.: Autoantibodyreactive with three classes of RNA polymerases in sera frompatients with systemic sclerosis. J. Clin. Invest., 1993; 91: 1399-1404
  Google Scholar
• 22. Lakota K., Thallinger G.G., Sodin-Semrl S., Rozman B., AmbrozicA., Tomsic M., Praprotnik S., Cucnik S., Mrak-Poljsak K., CeribelliA., Cavazzana I., Franceschini F., Vencovsky J., Czirjak L., Varju C.i wsp.: International cohort study of 73 anti-Ku-positive patients:association of p70/p80 anti-Ku antibodies with joint/bone features and differentiation of disease populations by using principal-componentsanalysis. Arthritis Res. Ther., 2012; 14: R2
  Google Scholar
• 23. Loizos N., Lariccia L., Weiner J., Griffith H., Boin F., Hummers L.,Wigley F., Kussie P.: Lack of detection of agonist activity by antibodiesto platelet-derived growth factor receptor α in a subset of normal andsystemic sclerosis patient sera. Arthritis Rheum., 2009; 60: 1145-1151
  Google Scholar
• 24. Maes L., Blockmans D., Verschueren P., Westhovens R., De BeeckK.O., Vermeersch P., Van den Bergh K., Burlingame R.W., Mahler M.,Bossuyt X.: Anti-PM/Scl-100 and anti-RNA-polymerase III antibodiesin scleroderma. Clin. Chim. Acta, 2010; 411: 965-971
  Google Scholar
• 25. Mahler M., Gascon C., Patel S., Ceribelli A., Fritzler M.J., SwartA., Chan E.K., Satoh M.: Rpp25 is a major target of autoantibodies tothe Th/To complex as measured by a novel chemiluminescent assay.Arthritis Res. Ther., 2013; 15: R50
  Google Scholar
• 26. Mahler M., Raijmakers R.: Novel aspects of autoantibodies tothe PM/Scl complex: clinical, genetic and diagnostic insights. Autoimmun.Rev., 2007; 6: 432-437
  Google Scholar
• 27. Masi A.T.: Preliminary criteria for the classification of systemicsclerosis (scleroderma). Subcommittee for scleroderma criteria ofthe American Rheumatism Association Diagnostic and TherapeuticCriteria Committee. Arthritis Rheum., 1980; 23: 581-590
  Google Scholar
• 28. Meyer O., De Chaisemartin L., Nicaise-Roland P., Cabane J., TubachF., Dieude P., Hayem G., Palazzo E., Chollet-Martin S., KahanA., Allanore Y.: Anti-RNA polymerase III antibody prevalence andassociated clinical manifestations in a large series of French patientswith systemic sclerosis: a cross-sectional study. J. Rheumatol.,2010; 37: 125-130
  Google Scholar
• 29. Mitri G.M., Lucas M., Fertig N., Steen V.D., Medsger T.A.Jr.: A comparisonbetween anti-Th/To – and anticentromere antibody-positivesystemic sclerosis patients with limited cutaneous involvement.Arthritis Rheum., 2003; 48: 203-209
  Google Scholar
• 30. Nihtyanova S.I., Denton C.P.: Autoantibodies as predictive toolsin systemic sclerosis. Nat. Rev. Rheumatol., 2010; 6: 112-116
  Google Scholar
• 31. Nihtyanova S.I., Parker J.C., Black C.M., Bunn C.C., Denton C.P.:A longitudinal study of anti-RNA polymerase III antibody levels insystemic sclerosis. Rheumatology, 2009; 48: 1218-1221
  Google Scholar
• 32. Nikpour M., Hissaria P., Byron J., Sahhar J., Micallef M., PaspaliarisW., Roddy J., Nash P., Sturgess A., Proudman S., Stevens W.:Prevalence, correlates and clinical usefulness of antibodies to RNApolymerase III in systemic sclerosis: a cross-sectional analysis ofdata from an Australian cohort. Arthritis Res. Ther., 2011; 13: R211
  Google Scholar
• 33. Parker J.C., Burlingame R.W., Bunn C.C.: Prevalence of antibodiesto Ro-52 in a serologically defined population of patients withsystemic sclerosis. J. Autoimmune Dis., 2009; 6: 2
  Google Scholar
• 34. Puszczewicz M.: Antinuclear antibodies – what to do with them?Reumatologia, 2013; 51: 172-178
  Google Scholar
• 35. Reveille J.D., Solomon D.H., American College of RheumatologyAd Hoc Committee of Immunologic Testing Guidelines: Evidence–based guidelines for the use of immunologic tests: anticentromere,Scl-70, and nucleolar antibodies. Arthritis Rheum., 2003; 49: 399-412
  Google Scholar
• 36. Rozman B., Cucnik S., Sodin-Semrl S., Czirjak L., Varju C., DistlerO., Huscher D., Aringer M., Steiner G., Matucci-Cerinic M., GuiducciS., Stamenkovic B., Stankovic A., Kveder T.: Prevalence and clinicalassociations of anti-Ku antibodies in patients with systemic sclerosis:a European EUSTAR-initiated multi-centre case-control study.Ann. Rheum. Dis., 2008; 67: 1282-1286
  Google Scholar
• 37. Russo K., Hoch S., Dima C., Varga J., Teodorescu M.: Circulatinganticentromere CENP-A and CENP-B antibodies in patients with diffuseand limited systemic sclerosis, systemic lupus erythematosus,and rheumatoid arthritis. J. Rheumatol., 2000; 27: 142-148
  Google Scholar
• 38. Satoh T., Ishikawa O., Ihn H., Endo H., Kawaguchi Y., Sasaki T.,Goto D., Takahashi K., Takahashi H., Misaki Y., Mimori T., Muro Y.,Yazawa N., Sato S., Takehara K. i wsp.: Clinical usefulness of anti-RNApolymerase III antibody measurement by enzyme-linked immunosorbentassay. Rheumatology, 2009; 48: 1570-1574
  Google Scholar
• 39. Sharif R., Fritzler M.J., Mayes M.D., Gonzalez E.B., McNearneyT.A., Draeger H., Baron M., the Canadian Scleroderma Research Group,Furst D.E., Khanna D.K., del Junco D.J., Molitor J.A., Schiopu E.,Phillips K., Seibold J.R., Silver R.M. i wsp.: Anti-fibrillarin antibodyin African American patients with systemic sclerosis: immunogenetics,clinical features, and survival analysis. J. Rheumatol., 2011;38: 1622-1630
  Google Scholar
• 40. Spencer-Green G., Alter D., Welch H.G.: Test performance insystemic sclerosis: anti-centromere and anti-Scl-70 antibodies. Am.J. Med., 1997; 103: 242-248
  Google Scholar
• 41. Tormey V.J., Bunn C.C., Denton C.P., Black C.M.: Anti-fibrillarinantibodies in systemic sclerosis. Rheumatology, 2001; 40: 1157-1162
  Google Scholar
• 42. van den Hoogen F., Khanna D., Fransen J., Johnson S.R., Baron M.,Tyndall A., Matucci-Cerinic M., Naden R.P., Medsger T.A.Jr., CarreiraP.E., Riemekasten G., Clements P.J., Denton C.P., Distler O., AllanoreY. i wsp.: Classification criteria for systemic sclerosis: an ACR-EULARcollaborative initiative. Arthritis Rheum., 2013; 65: 2737-2747
  Google Scholar
• 43. Villalta D., Imbastaro T., Di Giovanni S., Lauriti C., Gabini M.,Turi M.C., Bizzaro N.: Diagnostic accuracy and predictive value ofextended autoantibody profile in systemic sclerosis. Autoimmun.Rev., 2012; 12: 114-120
  Google Scholar
• 44. Villalta D., Morozzi G., Tampoia M., Alpini C., Brusca I., SalgaroloV., Papisch W., Bizzaro N.: Antibodies to fibrillarin, PM-Scl and RNApolymerase III detected by ELISA assays in patients with systemicsclerosis. Clin. Chim. Acta, 2010; 411: 710-713
  Google Scholar
• 45. Weiner E.S., Earnshaw W.C., Senecal J.L., Bordwell B., JohnsonP., Rothfield N.F.: Clinical associations of anticentromere antibodiesand antibodies to topoisomerase I. A study of 355 patients. ArthritisRheum., 1988; 31: 378-385
  Google Scholar
• 46. Zimmermann-Górska I.: Postępy 2013 – Twardzina układowa.http://www.mp.pl/reumatologia/postepy/show.html?id=102496(02.08.2014)
  Google Scholar

Full text